Loading...
XASEVNRX
Market cap62mUSD
Dec 24, Last price  
0.65USD
1D
5.69%
1Q
5.02%
Jan 2017
-85.82%
IPO
-83.80%
Name

VolitionRX Ltd

Chart & Performance

D1W1MN
XASE:VNRX chart
P/E
—
P/S
80.21
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
17.81%
Rev. gr., 5y
-20.63%
Revenues
775k
+153.04%
0000000054,968014,785000017,09613,43390,035306,392775,302
Net income
-35m
L+16.68%
-24,180-13,105-36,987-26,295-21,803-15,816-10,947-2,608,463-4,083,050-3,710,289-8,213,529-9,530,242-11,905,278-14,769,207-18,008,623-16,028,670-20,481,914-26,970,468-30,268,793-35,319,078
CFO
-18m
L+18.23%
-6335-49,999-17,31139,946-5,750-4,650-1,686,065-2,314,582-3,084,206-4,140,825-8,766,323-9,055,693-12,193,238-14,733,027-12,739,455-16,464,244-20,853,919-15,277,742-18,062,999
Earnings
Mar 24, 2025

Profile

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose a range of cancers and other diseases worldwide. It sells Nu.Q that detect cancer; Nu.Q Nets, monitoring the immune system; Nu.Q Vet cancer screening test for veterinary applications; Nu.Q Capture capturing and concentrating samples for more accurate diagnosis; and Nu.Q Discover, a solution to profiling nucleosomes. The company operates Nucleosomics a technology platform for blood test. VolitionRx Limited is based in Austin, Texas.
URL
https://volition.com/
IPO date
Feb 06, 2015
Employees
111
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
775
153.04%
306
240.30%
90
570.25%
Cost of revenue
36,471
32,926
28,294
Unusual Expense (Income)
NOPBT
(35,696)
(32,620)
(28,204)
NOPBT Margin
Operating Taxes
(330)
(19)
Tax Rate
NOPAT
(35,696)
(32,290)
(28,185)
Net income
(35,319)
16.68%
(30,269)
12.23%
(26,970)
31.68%
Dividends
Dividend yield
Proceeds from repurchase of equity
28,356
6,556
23,089
BB yield
-55.52%
-4.87%
-13.96%
Debt
Debt current
1,703
1,358
1,018
Long-term debt
5,429
4,743
3,948
Deferred revenue
Other long-term liabilities
423
420
253
Net debt
(13,598)
(4,766)
(15,616)
Cash flow
Cash from operating activities
(18,063)
(15,278)
(20,854)
CAPEX
(1,084)
(1,570)
(974)
Cash from investing activities
(1,084)
(1,570)
(974)
Cash from financing activities
28,983
6,938
22,858
FCF
(31,332)
(29,152)
(27,982)
Balance
Cash
20,730
10,867
20,581
Long term investments
Excess cash
20,691
10,852
20,577
Stockholders' equity
(203,161)
(167,524)
(137,009)
Invested Capital
200,977
169,791
159,001
ROIC
ROCE
1,634.58%
EV
Common stock shares outstanding
71,235
55,350
52,656
Price
0.72
-70.49%
2.43
-22.61%
3.14
-19.28%
Market cap
51,075
-62.03%
134,501
-18.65%
165,339
-6.13%
EV
36,567
129,183
149,502
EBITDA
(34,282)
(31,430)
(27,059)
EV/EBITDA
Interest
222
173
156
Interest/NOPBT